
Claims

1. Use of a controlled-release CNP agonist in the manufacture of a medicament for the treatment of achondroplasia in combination with human growth hormone, wherein the controlled-release CNP agonist is a compound of formula (IIf):




(IIf), or a pharmaceutically acceptable salt thereof;

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of a CNP moiety of SEQ ID NO:24 by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to -Z having the structure



,

wherein


each -Z^a is



wherein

each c1 is an integer independently ranging from 200 to 250.

2. The use of claim 1, wherein the controlled-release CNP agonist is a compound of formula (IIf ’):




(IIf ’), or a pharmaceutically acceptable salt thereof;

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of the CNP moiety of SEQ ID NO:24 by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to -Z having the structure



,

wherein


each -Z^a is



wherein

each c1 is an integer independently ranging from 200 to 250.

3. The use of claim 1 or 2, wherein the controlled-release CNP agonist is a compound of formula (IIf ’):




(IIf ’),

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of the CNP moiety of SEQ ID NO:24 by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to -Z having the structure



,

wherein

each -Z^a is



wherein each c1 is an integer independently ranging from 200 to 250.


4. The use of any one of claims 1 to 3, wherein each c1 is 225.

5. The use of any one of claims 1 to 4, wherein the human growth hormone is of SEQ ID NO:99.

6. The use of any one of claims 1 to 5, wherein the human growth hormone is in its free form.

7. The use of any one of claims 1 to 6, wherein the human growth hormone is in the form of a controlled-release compound.

8. The use of any one of claims 1 to 5 and 7, wherein the human growth hormone is of formula (A1):



(A1),

wherein n ranges from 200 to 250 and hGH is human growth hormone of SEQ ID NO:99.

9. The use of any one of claims 1 to 8, wherein the controlled-release CNP agonist and human growth hormone are formulated for simultaneous, separate or sequential administration.

10. The use of any one of claims 1 to 9, wherein the controlled-release CNP agonist and human growth hormone are formulated for sequential administration.

11. The use of any one of claims 1 to 9, wherein the controlled-release CNP agonist and human growth hormone are formulated for separate administration.